Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.02 USD
Change Today -0.09 / -1.27%
Volume 4.1M
PDLI On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

pdl biopharma inc (PDLI) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $10.26
52 Week Low
02/24/15 - $6.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PDL BIOPHARMA INC (PDLI)

Related News

No related news articles were found.

pdl biopharma inc (PDLI) Related Businessweek News

No Related Businessweek News Found

pdl biopharma inc (PDLI) Details

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. has license agreements with various biotechnology and pharmaceutical companies, as well as acquires royalty and other assets. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

10 Employees
Last Reported Date: 02/23/15
Founded in 1986

pdl biopharma inc (PDLI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $716.1K
Chief Financial Officer and Vice President
Total Annual Compensation: $405.6K
Vice President, General Counsel and Secretary
Total Annual Compensation: $415.8K
Chief Accounting Officer and Controller
Total Annual Compensation: $249.6K
Vice President of Business Development
Total Annual Compensation: $343.1K
Compensation as of Fiscal Year 2014.

pdl biopharma inc (PDLI) Key Developments

PDL BioPharma, Inc. Announces Resignation of David Montez as Controller and Chief Accounting Officer, Effective May 15, 2015

PDL BioPharma, Inc. announced that on April 22, 2015, David Montez, the Controller and Chief Accounting Officer of the company, entered into a Separation Agreement whereby he resigned from the company, such resignation to be effective as of May 15, 2015. In addition, Mr. Montez will be retained as a consultant to support the transition to a new chief accounting officer for the Company for a six month period following his resignation.

PDL BioPharma, Inc. Enters into Credit Agreement for Term Loan of $100,000,000

On March 30, 2015, PDL BioPharma, Inc. (the Company) entered into a credit agreement among the company, the lenders party thereto, and Royal Bank of Canada as administrative agent. The Credit Agreement consists of a term loan of $100,000,000, with a term that expires on February 15, 2016. The interest rates per annum applicable to amounts outstanding under the term loan are, at the company's option, either the alternate base rate plus 0.75%, or the adjusted Eurodollar rate plus 1.75% per annum. Interest payments under the Credit Agreement are due on the interest payment dates specified in the Credit Agreement. The term loan requires amortization in the form of quarterly scheduled principal payments as specified in the Credit Agreement. Any future material domestic subsidiaries of the company are required to guarantee the obligations of the company under the Credit Agreement, except as otherwise provided by the Credit Agreement. The company's obligations under the Credit Agreement are secured by a lien on a substantial portion of its assets. The Credit Agreement contains events of default that the Company believes are usual and customary for a senior secured credit agreement.

PDL BioPharma, Inc. Announces Dismissal of Third and Final Shareholder Lawsuit

PDL BioPharma, Inc. announced that the third of three shareholder lawsuits filed in the fall of 2014, was voluntarily dismissed without prejudice. On February 2, 2015, a securities lawsuit that was filed against the company last September on behalf of a putative class of purchasers of the company's stock, Hampe v. PDL Biopharma, Inc., et al., No. 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily dismissed without prejudice. Shortly thereafter, and in light of the dismissal of the Hampe case, two derivative lawsuits filed against the company's directors, which were based on nearly identical substantive allegations to those made in the Hampe lawsuit, were similarly voluntarily dismissed without prejudice. The two derivative suits, Feely, et ano. v. Lindell, et al., No. 2:14-CV-01738-APG-GWF (D. Nev.) and Marchetti, et ano. v. Lindell, et al., No. A-14-708757-C (Dist. Ct. Clark Co., Nev.), were dismissed on February 17, 2015 and February 18, 2015, respectively. This notice is provided to shareholders of the company pursuant to the direction of the courts that dismissed the derivative lawsuits. The company is subject to no ongoing securities or shareholder lawsuits.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDLI:US $7.02 USD -0.09

PDLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €9.12 EUR +0.12
BioInvent International AB kr2.07 SEK -0.01
Genmab A/S kr545.50 DKK +21.00
XOMA Corp $3.60 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation PDLI Industry Range
Price/Earnings 3.8x
Price/Sales 2.3x
Price/Book 2.5x
Price/Cash Flow 3.6x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDL BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at